



(51) International Patent Classification:

A61K 35/17 (2025.01) *A61P 19/00* (2006.01)
A61K 35/12 (2015.01) *C12N 15/12* (2006.01)
A61K 35/28 (2015.01)

(21) International Application Number:

PCT/US2024/054285

(22) International Filing Date:

01 November 2024 (01.11.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/595,741	02 November 2023 (02.11.2023)	US
63/623,768	22 January 2024 (22.01.2024)	US
63/643,222	06 May 2024 (06.05.2024)	US
63/660,968	17 June 2024 (17.06.2024)	US
63/698,944	25 September 2024 (25.09.2024)	US

(71) Applicant: **BE BIOPHARMA, INC.** [US/US]; One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US).

(72) Inventors: **LIU, Hanlan**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **LEACH, Sarah Grace**; c/o

Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **BAIN-TER, JR., Wayne**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **CLEMENTS, Madison Ashley**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **MORGAN, Richard A.**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **MULLEN, Timothy James**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **HOHMANN, Anja Fides**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **DASTAGIR, Shamael Rabbia**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **GUJJA, Sharvari**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **KEEGAN, Sean Patrick**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **STANLIE, Andre**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, Massachusetts 02139 (US). **OHSUMI, Toshiro Kendrick**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cam-

(54) Title: ENGINEERED CELL PREPARATIONS FOR TREATMENT OF HYPOPHOSPHATASIA




FIGURE 1A

(57) Abstract: The present disclosure provides methods and compositions for culturing, engineering, and administering engineered B lineage cell populations that produce an ALP or a fusion protein thereof, such as ALP-Fc fusion protein comprising alkaline phosphatase and human immunoglobulin fragment crystallizable region.

[Continued on next page]

bridge, Massachusetts 02139 (US). **MUSIAL-SIWEK, Monika**; c/o Be Biopharma, Inc., One Kendall Square, Building 200, Third Floor, Cambridge, MA 02139 (US).

(74) **Agent: KITTO, Rebekah Z.** et al.; Choate, Hall & Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(88) **Date of publication of the international search report:**
10 July 2025 (10.07.2025)